This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Canopy Growth Earnings After Bell 6/20: Key Word Growth
by Daniel Laboe
CGC analysts are estimating an EPS of -0.17 and revenues of $71 million. Shareholders are voting today on whether to acquire Acreage Holdings, which could propel CGC one way or the other.
What to Expect from Marijuana Giant Canopy Growth's (CGC) Q4 Earnings
by Zachary Stutler
Canopy's stock is up 58% YTD, but all of this growth came in the first month of the year and the stock has struggled to maintain the levels it hit earlier this year.
Medical Products Industry Outlook: Growth Prospects Radiant
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
What's in the Offing for HEXO Corp's (HEXO) Q3 Earnings?
by Zacks Equity Research
HEXO Corp's (HEXO) recent 1,000,000 sq. ft. greenhouse expansion is likely to reflect on quarterly results.
Do Hemp Stocks Stand to Gain From a Weed-Liberal Illinois?
by Nitish Marwah
The marijuana legislation in Illinois would allow any resident of the state above the age of 21 to possess the novelty item.
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Canopy Growth, Aurora Cannabis and Hexo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Canopy Growth, Aurora Cannabis and Hexo
4 CBD Stocks to Win Big in June
by Tirthankar Chakraborty
Analysts estimate that nearly 65 million Americans have tried CBD and 63% have found it effective. What's more, CBD is a growing industry with sales expected to rise 55% to $648 million in 2019.
FDA to Hold First Public Hearing on Cannabis: 5 Likely Gainers
by Nalak Das
Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.
Marijuana Stocks & ETFs: What Investors Need to Know
by Neena Mishra
Here is what investors need to know about cannabis investing and the first actively managed pot ETF.
The Cannabis Craze
by Daniel Laboe
The "Cannabis Craze" had everyone and their brother buying up marijuana stocks. These cannabis stocks didn't have enough free-floating shares to cover the massive amount of buy interest leading them to skyrocketed at the end of 2018 far above their fair value.
Why Aurora Cannabis (ACB) Might Surprise This Earnings Season
by Zacks Equity Research
Aurora Cannabis (ACB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Marijuana ETFs Head-to-Head
by Neena Mishra
Here is what investors need to know about cannabis investing and the two ETFs that provide exposure to the space.
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Scott's Miracle Grow, GW Pharmaceuticals, Canopy Growth, Tilray and Aurora Cannabis
What's in Store for Aurora Cannabis (ACB) in Q3 Earnings?
by Zacks Equity Research
Continued execution of consumer and medical strategies, launch of new products and strong international footprint are likely to aid Aurora Cannabis (ACB) in Q3.
Buy Marijuana Stocks, Tilray & Aurora Cannabis, Before Earnings?
by Benjamin Rains
The legal marijuana industry is still in the early stages, so let's see if investors should consider buying some pure-play marijuana stocks heading into earnings.
Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis (ACB) likely to gain from solid prospects in the Canadian and international consumer markets in fiscal Q3.
5 Pot Stock Earnings Charts
by Tracey Ryniec
It's an emerging industry, but are companies actually beating on earnings?
Aurora Cannabis Inc. (ACB) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $8.88, marking a +1.02% move from the previous day.
Inogen (INGN) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.
What's in the Cards for Axon Enterprise (AAXN) Earnings?
by Zacks Equity Research
Axon Enterprise's (AAXN) expanded product offerings and strong execution likely to drive its first-quarter 2019 performance.
Can BD Medical Drive Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects BD Medical to drive fiscal Q2 results; foreign exchange headwinds persist.
Can Core Business Unit Fuel McKesson (MCK) Q4 Earnings?
by Zacks Equity Research
Anticipated growth across core business unit and solid show by Medical Surgical and European Pharmaceutical Solutions is likely to aid McKesson's (MCK) Q4 earnings. However, rising costs might be a dampener.
What's in Store for Cardinal Health (CAH) in Q3 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments and diverse product portfolio is likely to aid Cardinal Health (CAH) in Q3 earnings. However, stiff competition might play spoilsport.
The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GW, Innovative Industrial, Canopy, Aurora and KushCo
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
Better-than-expected performance at Kidney Care, strategic buyouts and international expansion might aid DaVita (DVA) in Q1. However, integration risks might be a dampener.